CR8705A - Regimen de dosificacion en combinacion para eritropoyteina - Google Patents
Regimen de dosificacion en combinacion para eritropoyteinaInfo
- Publication number
- CR8705A CR8705A CR8705A CR8705A CR8705A CR 8705 A CR8705 A CR 8705A CR 8705 A CR8705 A CR 8705A CR 8705 A CR8705 A CR 8705A CR 8705 A CR8705 A CR 8705A
- Authority
- CR
- Costa Rica
- Prior art keywords
- combination
- epo
- reticulocytes
- exposure
- dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invencion provee un regimen de dosificacion en combinacion para eritopoyetina (EPO); en particular, el regimen de dosificacion de la presente incluye la administracion de por lo menos un primer segmento de dosificacion que comprende una primera exposicion a EPO capaz de estimular la produccion de reticulocitos seguida por una segunda exposicion a EPO capaz de sostener la maduracion de los reticulocitos en neocitos, y finalmente, globulos rojos; ventajosamente, el segmento de dosificacion se puede ciclar o repetir, cualquier numero de veces y de acuerdo con cualquier esquema de tiempo deseado, con el fin de proveer o mantener cualquier conteo de globulos rojos y/o concentracion de hemoglobina total deseado; tambien se proveen metodos de tratamiento que emplean el regimen de dosificacion en combinacion asi como equipos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55692304P | 2004-03-26 | 2004-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR8705A true CR8705A (es) | 2008-09-09 |
Family
ID=34964370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR8705A CR8705A (es) | 2004-03-26 | 2006-10-25 | Regimen de dosificacion en combinacion para eritropoyteina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050267026A1 (es) |
| EP (1) | EP1737484A1 (es) |
| JP (1) | JP2007530578A (es) |
| KR (1) | KR20070015549A (es) |
| CN (1) | CN1960745A (es) |
| AU (1) | AU2005231307A1 (es) |
| BR (1) | BRPI0509239A (es) |
| CA (1) | CA2561222A1 (es) |
| CR (1) | CR8705A (es) |
| EA (1) | EA010889B1 (es) |
| EC (1) | ECSP066885A (es) |
| IL (1) | IL178288A0 (es) |
| MX (1) | MXPA06011084A (es) |
| NO (1) | NO20064908L (es) |
| UA (1) | UA89630C2 (es) |
| WO (1) | WO2005097167A1 (es) |
| ZA (1) | ZA200608877B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150164991A1 (en) * | 2013-11-01 | 2015-06-18 | Vanderbilt University | Method and Kit for Evaluating and Monitoring a Treatment Program for Anemia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0010316A (pt) * | 1999-05-11 | 2004-04-27 | Ortho Mcnell Pharmaceutical In | Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente |
| KR100693263B1 (ko) * | 1999-07-22 | 2007-03-13 | 아벤티스 파마슈티칼스 인크. | 다중 투여형 에리트로포이에틴 제형 |
| CN1309416C (zh) * | 2000-05-15 | 2007-04-11 | 霍夫曼-拉罗奇有限公司 | 新的药物组合物 |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
-
2005
- 2005-03-24 UA UAA200610352A patent/UA89630C2/ru unknown
- 2005-03-24 US US11/088,284 patent/US20050267026A1/en not_active Abandoned
- 2005-03-24 EA EA200601782A patent/EA010889B1/ru not_active IP Right Cessation
- 2005-03-24 WO PCT/US2005/009873 patent/WO2005097167A1/en active Application Filing
- 2005-03-24 JP JP2007505184A patent/JP2007530578A/ja active Pending
- 2005-03-24 CA CA002561222A patent/CA2561222A1/en not_active Abandoned
- 2005-03-24 MX MXPA06011084A patent/MXPA06011084A/es unknown
- 2005-03-24 AU AU2005231307A patent/AU2005231307A1/en not_active Abandoned
- 2005-03-24 EP EP05731453A patent/EP1737484A1/en not_active Ceased
- 2005-03-24 CN CNA2005800171911A patent/CN1960745A/zh active Pending
- 2005-03-24 KR KR1020067022204A patent/KR20070015549A/ko not_active Application Discontinuation
- 2005-03-24 BR BRPI0509239-6A patent/BRPI0509239A/pt not_active IP Right Cessation
-
2006
- 2006-09-25 IL IL178288A patent/IL178288A0/en unknown
- 2006-09-26 EC EC2006006885A patent/ECSP066885A/es unknown
- 2006-10-25 CR CR8705A patent/CR8705A/es not_active Application Discontinuation
- 2006-10-25 ZA ZA200608877A patent/ZA200608877B/en unknown
- 2006-10-26 NO NO20064908A patent/NO20064908L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0509239A (pt) | 2007-09-04 |
| EP1737484A1 (en) | 2007-01-03 |
| EA010889B1 (ru) | 2008-12-30 |
| KR20070015549A (ko) | 2007-02-05 |
| MXPA06011084A (es) | 2007-03-21 |
| ZA200608877B (en) | 2008-06-25 |
| WO2005097167A1 (en) | 2005-10-20 |
| JP2007530578A (ja) | 2007-11-01 |
| UA89630C2 (ru) | 2010-02-25 |
| AU2005231307A1 (en) | 2005-10-20 |
| EA200601782A1 (ru) | 2007-04-27 |
| CA2561222A1 (en) | 2005-10-20 |
| NO20064908L (no) | 2006-12-15 |
| IL178288A0 (en) | 2006-12-31 |
| US20050267026A1 (en) | 2005-12-01 |
| CN1960745A (zh) | 2007-05-09 |
| ECSP066885A (es) | 2006-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150523A (es) | Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas | |
| UY38160A (es) | Partículas implantables y métodos relacionados | |
| BRPI0518869A2 (pt) | agentes citotàxicos compreendendo taxanos | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| CR20140352A (es) | Anticuerpo anti-epirregulina humanizado y agente terapéutico contra el cáncer que comprende dicho anticuerpo como ingrediente activo | |
| AR056801A1 (es) | Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina | |
| AR051446A1 (es) | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) | |
| DOP2006000057A (es) | Composición farmaceútica para el tratamiento del cáncer | |
| AR054683A1 (es) | Capuchon para dispositivos para la administracion de farmacos | |
| PA8654201A1 (es) | Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2 | |
| NO20060955L (no) | Farmasoytisk sammensetning som er nyttig til stamcellemobilisering | |
| UY28271A1 (es) | Compuestos químicos | |
| WO2005117542A3 (en) | Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments | |
| BRPI0506888A (pt) | composições de suplemento lìquido compreendendo um ou mais medicamentos | |
| AR086395A1 (es) | Envase para el tratamiento de patologias | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| AR086315A1 (es) | Metodo y composicion para tratamiento de semillas | |
| BR112018013896A2 (pt) | formulações para o tratamento do câncer de bexiga | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| CL2013002700A1 (es) | Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros | |
| PA8574001A1 (es) | Uso de docetaxel en combinacion con doxorrubicina y ciclofosfamida como terapia adyuvante | |
| UY28366A1 (es) | Compuestos químicos | |
| AR057648A1 (es) | Composicion de metaflumizona para la administracion topica | |
| CO2022013055A2 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| CR8705A (es) | Regimen de dosificacion en combinacion para eritropoyteina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |